189 results
Page 3 of 10
6-K
EX-99.3
vlzhrgu qif
10 May 22
Replicel Life Sciences Inc. Announces Application for a Management Cease Trade Order
4:34pm
6-K
EX-99.4
7a3hs03kti7vo5
10 May 22
Replicel Life Sciences Inc. Announces Application for a Management Cease Trade Order
4:34pm
6-K
EX-99.1
kcev0jg
29 Mar 22
RepliCel Announces Non-brokered Private Placement
1:02pm
6-K
EX-99.1
jjdlhc7ginahtzerhf
29 Mar 22
RepliCel Announces Material Patent Milestones
12:51pm
6-K
EX-99.2
vdxdxrbwjjhwlnol3f7
21 Dec 21
51-102F3 Material Change Report
5:28pm
6-K
EX-99.3
4srpau mdaanb1q
21 Dec 21
51-102F3 Material Change Report
5:28pm
6-K
EX-99.1
3xrpxd6bv t22
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.2
3eiprc xl8w4u5die
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.1
0xyma321j0fj50
16 Nov 21
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
4:03pm
6-K
EX-99.2
9o84ca53h53ei xg8
16 Nov 21
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
4:03pm
6-K
EX-99.2
f3kxn6hnzsv p9lflq
2 Nov 21
RepliCel Announces Dermal Injector Update
12:31pm
6-K
EX-99.1
jf4b72x yqtuy5l
2 Nov 21
RepliCel Announces Dermal Injector Update
12:31pm
6-K
EX-99.3
ley54 ikwg
2 Nov 21
RepliCel Announces Dermal Injector Update
12:31pm
6-K
EX-99.1
cf7dkka v620pk
21 Oct 21
Current report (foreign)
3:49pm
6-K
EX-99.1
63zawa75rgzb1
14 Oct 21
51-102F3 Material Change Report
4:00pm
6-K
EX-99.1
8msbfksdvjna12prgx
13 Oct 21
RepliCel Life Sciences Appoints One of Japan’s Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
12:00am
6-K
EX-99.1
6fc75furmtn46r2dxkrl
12 Oct 21
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents
1:06pm
6-K
EX-99.2
o1f51sxos674udm
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
EX-99.1
vir5id
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
EX-99.1
p9b0c n6optfuue
18 Aug 21
RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Cell Therapies
12:38pm